Receptor News and Research

RSS

FDA grants Breakthrough Therapy designation to Syndax's entinostat for ER+ breast cancer

Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy.

12 Sep 2013

Biogen Idec, Amicus Launch Parkinson's Collaboration

...

10 Sep 2013

Amino acid arginine improves treatment for type 2 diabetes

More than 371 million people worldwide suffer from diabetes, of whom 90% are affected by lifestyle-related diabetes mellitus type 2 (type 2 diabetes).

10 Sep 2013

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Combination therapy with pemetrexed and erlotinib significantly improves progression-free survival as compared with either drug alone in patients with advanced non-squamous non-small-cell lung cancer, a phase II study has found.

9 Sep 2013

Researchers find key mechanism behind Alzheimer's disease

Alzheimer's disease affects more than 26 million people worldwide. It is predicted to skyrocket as boomers age-nearly 106 million people are projected to have the disease by 2050.

7 Sep 2013

Chemotherapy best second-line option for EGFR wild-type NSCLC

Chemotherapy is more effective than erlotinib as second-line therapy in people with advanced non-small-cell lung cancer and wild-type epidermal growth factor receptor genotype, a randomized controlled trial has found.

5 Sep 2013

Karo Wins First Milestone For Autoimmune Disease Deal With Pfizer

...

5 Sep 2013

Sirt1 Protein, Not Calorie Restriction, Extends Life Span

...

4 Sep 2013

New mechanism operates specific protein in brain to bring delay in aging

Among scientists, the role of proteins called sirtuins in enhancing longevity has been hotly debated, driven by contradictory results from many different scientists. But new research at Washington University School of Medicine in St. Louis may settle the dispute.

4 Sep 2013

Debiopharm starts Debio 1347 phase I study in patients with advanced solid tumors

Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.

2 Sep 2013

Pre-treatment with prasugrel increases risk of bleeding without reducing risk of ischemic events

In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist prasugrel prior to catheterization, significantly increases the risk of life-threatening bleeding without reducing the risk of major ischemic events, according to the results of the ACCOAST (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction) trial.

2 Sep 2013

Researchers develop model that completes bridge between cellular and human studies of schizophrenia

Schizophrenia is one of the most devastating neurological conditions, with only 30 percent of sufferers ever experiencing full recovery. While current medications can control most psychotic symptoms, their side effects can leave individuals so severely impaired that the disease ranks among the top ten causes of disability in developed countries.

31 Aug 2013

Scientists unravel how DNA damage may trigger lupus erythematosus

Summer, sun and the sea - a dream vacation for most - can turn sour for those affected by lupus erythematosus. For them, absorption of the UV-light component in sunlight may cause florid inflammation and redness of the skin. Scientists of the University Hospital Bonn, Germany have now discovered which signaling pathway of the innate immune system promotes autoimmune symptoms following sun-induced DNA damage.

30 Aug 2013

Protein activated by inflammation converts glioblastoma multiforme cells to most aggressive form

A prominent protein activated by inflammation is the key instigator that converts glioblastoma multiforme cells to their most aggressive, untreatable form and promotes resistance to radiation therapy, an international team lead by researchers at The University of Texas MD Anderson Cancer Center reported online today in the journal Cancer Cell.

30 Aug 2013

Study explains how sensory input impacts fruit flies' decisions about sweet taste

Fruit flies have a lot to teach us about the complexity of food. Like these tiny little creatures, most animals are attracted to sugar but are deterred from eating it when bitter compounds are added.

29 Aug 2013

Malignant Hyperthermia Scientific Conference to be held at University of Toronto

The 2013 Malignant Hyperthermia (MH) Scientific Conference is being held at the Chestnut Conference Centre, University of Toronto, Canada on November 1st and 2nd, 2013 and is sponsored by Malignant Hyperthermia Association of the United States (MHAUS) in conjunction with The University of Toronto.

29 Aug 2013

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

OxyContin contains oxycodone, which is an opioid agonist. It is used for the management of moderate to severe pain when a constant opioid analgesic is needed for a prolonged period of time.

29 Aug 2013

NAMS publishes new guidance for diagnosing and treating vulvovaginal atrophy

Symptoms of vulvovaginal atrophy (VVA), such as lack of lubrication, irritated tissues, painful urination, and pain with intercourse, affect as many as 45% of women after menopause.

29 Aug 2013

Research findings may help scientists develop anthrax treatments for humans

Researchers at the National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute, both part of the National Institutes of Health, have identified the cells in two distinct areas of the body that are simultaneously targeted for damage by anthrax toxins, eventually causing illness and sometimes death. Their findings, which appeared online today in Nature, are based on testing in mice.

29 Aug 2013

Personality may be key to genetics of bipolar disorder

People with bipolar disorder vary significantly from their unaffected relatives, and from healthy controls, on several measures of personality, a study shows.

28 Aug 2013

Receptor News and Research

FDA grants Breakthrough Therapy designation to Syndax's entinostat for ER+ breast cancer

Biogen Idec, Amicus Launch Parkinson's Collaboration

Amino acid arginine improves treatment for type 2 diabetes

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Researchers find key mechanism behind Alzheimer's disease

Chemotherapy best second-line option for EGFR wild-type NSCLC

Karo Wins First Milestone For Autoimmune Disease Deal With Pfizer

Sirt1 Protein, Not Calorie Restriction, Extends Life Span

New mechanism operates specific protein in brain to bring delay in aging

Debiopharm starts Debio 1347 phase I study in patients with advanced solid tumors

Pre-treatment with prasugrel increases risk of bleeding without reducing risk of ischemic events

Researchers develop model that completes bridge between cellular and human studies of schizophrenia

Scientists unravel how DNA damage may trigger lupus erythematosus

Protein activated by inflammation converts glioblastoma multiforme cells to most aggressive form

Study explains how sensory input impacts fruit flies' decisions about sweet taste

Malignant Hyperthermia Scientific Conference to be held at University of Toronto

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

NAMS publishes new guidance for diagnosing and treating vulvovaginal atrophy

Research findings may help scientists develop anthrax treatments for humans

Personality may be key to genetics of bipolar disorder

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News